Common Contracts
1 similar Screening Agreement contracts
OcellO and Merus Sign Agreement for Screening Bispecific Cancer AntibodiesScreening Agreement • September 26th, 2022
Mark Throsby, Chief Operating Officer at Merus, commented: “The strength of our approach is its ability to generate thousands of full-length, bispecific human IgG antibodies addressing combinations of targets expressed by tumor cells. OcellO is able to provide high quality data on the functional properties of large panels of bispecific antibodies. These data can’t be obtained from other in vitro screening assays and are pivotal in identifying antibody leads with unique modes of action.
